Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Oxford Biomedica Plc | OXB | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 1.00 | 0.24% | 413.50 | 12:57:36 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 400.50 | 400.50 | 415.00 | 412.50 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 15/11/2024 08:09 by gareth jones London Healthcare Conference, the largest healthcare dedicated conference in Europe. OXB CEO and CFO presenting,attending with the presentation available to investors via the website. I don't think they will be revealing bad news? |
Posted at 15/11/2024 07:10 by takeiteasy OXB to present at the Jefferies London Healthcare ConferenceOxford, UK - 15 November 2024: OXB (LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces that Dr. Frank Mathias, Chief Executive Officer, will present at the Jefferies London Healthcare Conference on Tuesday, 19 November 2024 at 10:00am GMT. Dr. Lucy Crabtree, Chief Financial Officer, will also be participating in the conference. The presentation will be made available in the Investors section of OXB's website at www.oxb.com. |
Posted at 11/11/2024 12:23 by takeiteasy The Trump victory seems to be influencing the investors into favouring certain parts of the market atm (e.g. BTC, US small cap) and I wonder what influence this has on the UK mid cap world especially with the recent budget influences to work through.This may mean a lot more patience in the interim - let's wait and see as they say :) |
Posted at 04/11/2024 10:27 by takeiteasy Not impossible - interesting just how few firms from the health sector are linked to FTSE 250...look at the big investors in this area e.g. Mercantile IT close to zero investment in this sector and as you look at all the other names it follows a very similar pattern.We need firms like OXB to build a strong and stable franchise that develops some level of dull and boring predictability that the institutional investors would be looking for using their so called " data screens" based on investment output stats on risk and return and market cap data. This share seems so thinly traded that it takes a small puff of wind to more the dial up thank goodness near term so we do not need a huge push from bigger IIs but do hope later into 2025 that all the IR push we are making towards this cohort starts to show up a bit more. Getting back over 430 today may bring back the momentum crowd...wdik.. |
Posted at 31/10/2024 10:41 by harry s truman I agree Dom.I think a US company has to put out a lot more news as the investors demand to be kept up to speed. They also tend to report quarterly (even smaller companies) and have those federal "state of play" form submissions which are a mandatory record and anyone can look up. The trouble is that we are basically Anglo-French now, which is a combination of corporate modesty (not on to show off) coupled with snappy dressing and better food. We were told that we were trading the pipeline page and those RNS of the type "undisclosed partner / indication / financial details" for the KPI table. It does seem we are only going to get that twice per year though. I still think market sensitive news will get us the old style RNS as they are obliged to do that. |
Posted at 29/10/2024 17:52 by steeplejack Yes,equities could bounce back,the weakness is partly technical,resulting from the paranoia that this Government has managed to inject into the investment climate as it flays about looking to fine tune its tax grab.However,i doubt this administration will do anything to advance the cause of UK equity ownership,a market which has been well down the international league table over the last quarter century. Labour seem to have a belief that the public sector is in someway more inherently worthy and capable of orchestrating beneficial changes than a freewheeling private sector.They might be right yet this government reminds me constantly of the allegorical book Animal Farm.Selling gilts is one thing but attracting overseas investors to UK equities might be difficult especially if Trump is pedalling unbridled capitalism in the US.Meanwhile the attraction of smaller UK equities could be significantly diminished by AIM losing the IHT concession which it needs given that markets woeful performance.However, |
Posted at 07/10/2024 15:36 by philh75 It does seem suspicious when a large volume of shares is traded—like the 600k shares and yet the price remains static at £3.85. This could indicate some deliberate action or unusual market dynamics. Here are a few possible explanations for what might be happening:1. Market Maker Activity • Market makers (or large institutional players) could be trying to keep the stock price at £3.85 for various reasons. Market makers provide liquidity and are often involved in large trades behind the scenes. They can control the price by absorbing both buying and selling pressure to keep the price stable, especially if there’s an agreement to prevent significant volatility. 2. Accumulation Without Affecting Price • Someone could be accumulating shares at this price without wanting to trigger a price increase. By managing the trades carefully, the buyer might avoid pushing the price higher while still building a position. This tactic is common if an investor expects future news or growth but wants to buy as much as possible at a low price without alerting the broader market. 3. Order Book Manipulation • It’s possible there are large sell orders placed around the £3.85 mark to create resistance. This can be done by traders or institutions that want to prevent the price from rising for a specific reason, such as preparing for a large short position or to complete their buying at a low level. 4. Consolidation Phase • The stock may be going through a consolidation phase where both buyers and sellers are evenly matched, leading to a narrow trading range around £3.85. During this phase, the price stays flat despite heavy trading, as buyers and sellers balance each other out. This often happens before a breakout, either up or down, once one side takes control. 5. Pending News • If there is major news expected soon (such as a partnership announcement or earnings release), some investors may be positioning themselves in anticipation, while others may be holding back, creating a temporary standoff. Market makers or insiders with better knowledge of the situation may try to control volatility until the news is made public. In summary, while it may seem frustrating to see no price movement despite a high trading volume, it could be part of a larger strategy by institutional players or market makers to keep the stock price at a specific level for the time being. If there’s no major movement soon, it might be a sign that something significant is coming, or the stock is gearing up for a breakout once these constraints are lifted. |
Posted at 27/9/2024 14:32 by steeplejack I don’t have great confidence in technical analysis.Charts can be useful,afterall every picture tells a story but i question their predictive capabilities.I’One of the most satisfying aspects of investment is spotting recovery situations.So much financial commentary goes towards the big cap momentum trades ie whether one should be chasing the Nvidias or Novos but a bombed out oversold stock can easily double in short order without much acclaim.OXB has done just that in the last 12 months and averaging has enabled me to get into profit.As Brucie comments,nowadays with momentum trading etc,its easy enough to join the feeding frenzy surrounding the more fashionable trades .The difficulty is knowing when to jump ship and sell.I don’t think most investors are very good at knowing when to sell,i know i’m not and when you have the added complication of capital gains tax,its not always a level playing field,other considerations interfere.Of course,you should never fall in love with a stock,it can cloud your judgement.However,we here are all major beneficiaries of Harry’s love of OXB. |
Posted at 23/9/2024 17:32 by harry s truman Investor's Chronicle positive? That has to be a sign of the end of the world.Results & Trading Updates Revamped OXB moves closer to profitability Forthcoming client drug launches should support the group’s growth ambitions Published on September 23, 2024 by Jennifer Johnson Losses narrowing Momentum behind the shares Earlier this month, Oxford Biomedica announced the launch of its new corporate brand — OXB (OXB) — designed to reinforce what management calls “its transformation into a global pure-play cell and gene therapy CDMO". To investors, this probably looks like an attempt to distance itself from the vaccine manufacturing contract that brought it into the public consciousness – and that’s no bad thing. (Can't see the rest of it) OXB:LSE Oxford Biomedica PLC |
Posted at 30/7/2024 08:51 by harry s truman takeiteasy,As you will have worked out from many previous posts, when we had that regular run of news between the interims and the FY results last year, I had hoped that Frank was a new broom with regard to the relationship with small investors. I was particularly pleased with that idea as, with him coming from a successful unlisted company, I thought small investor relations might have been a bit of a mystery to him. Six months later and I'm more of the mind now that the ABL deal was such a big thing for OXB that he simply made a concerted effort to keep the market (and therefore us) onside during the overrun period after the expected / forecast deal close date. Since then it's been pretty much back to normal for OXB IR with good results presentations twice per year and the odd RNS in-between but nothing like a running commentary. I don't think it's anything bad (in fact I'm convinced of that) and would remind you of last year when we went into the interims thinking that there was only the Cabaletta deal which was new and of any significance, at which point OXB told us that there was the Cabaletta extension + another 10. If it helps at all, then remember that it's only really us sat in this "pot watching" position. Part of Roch's job as chairman is to brief the non-execs and keep the listed major shareholders onside. So they will all know how it's going in a general way (not names and contract values, but meeting / exceeding stated targets and how busy the sales dept. is etc.). If we get through tomorrow (last day of July of course) without that "quarterly update" then I would forget about that becoming a thing until winter, simply because I think they realise it it will look daft making some kind of mini-quarterly presentation in August and then the full interim results in September. On the other hand a simple business update or significant contract RNS can come any time. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
